Prostate Cancer - Results from #1620

Timing of High-Dose Rate Brachytherapy with External Beam Radiotherapy in intermediate and high-risk localised Prostate Cancer (THEPCA): a randomised trial. January 5, 2024

Approach to Patients with High-Risk Localized Prostate Cancer: Radiation Oncology Perspective. January 5, 2024

PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression. January 5, 2024

First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer. January 4, 2024

Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer. January 4, 2024

Unmet sexual health resource needs and preferences for interventions to address these needs among female partners of patients with prostate cancer. January 4, 2024

Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision. January 4, 2024

Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study. January 4, 2024

Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer. January 4, 2024

Quantifying Intrafraction Motion and the Impact of Gating for MRI-guided Stereotactic Radiotherapy for Prostate Cancer: Analysis of the MRI arm from the MIRAGE Phase III Randomized Trial. January 3, 2024

User-Centered Design and Usability of a Culturally Adapted Virtual Survivorship Care App for Chinese Canadian Prostate Cancer Survivors: Qualitative Descriptive Study. January 3, 2024

Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. January 3, 2024

Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase January 3, 2024

The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis. January 3, 2024

Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer. January 2, 2024

Potential roles of FGF5 as a candidate therapeutic target in prostate cancer. January 2, 2024

In Vitro Prostate Cancer Treatment via CRISPR-Cas9 Gene Editing Facilitated by Polyethyleneimine-Derived Graphene Quantum Dots. January 2, 2024

Association of neighborhood gentrification with prostate cancer and immune markers in African American and European American men. January 2, 2024

FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. January 2, 2024

Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy. January 2, 2024

Page 82 of 1439